Skip to content

Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain

Potential Off-label Use of Desloratadine to Mitigate Inflammation Caused by PPE-induced Heat Stress

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05446480
Enrollment
12
Registered
2022-07-06
Start date
2022-07-31
Completion date
2023-08-31
Last updated
2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Firefighter Personal Protective Equipment, Heat Stress, Exertional, Inflammatory Response

Brief summary

The aim of this initial investigational study is to compare the effect of desloratadine on the inflammatory responses to heat stress in firefighters exercising in their personal protective equipment.

Detailed description

Significant heat strain where temperatures approach and exceed 39.0 degrees celsius is known to increase intestinal permeability and induce a graded systemic inflammatory response which includes increases in interleukin-6, tumor necrosis factor alpha, and c-reactive protein. Recent data examining firefighters found fire service instructors possessed greater resting levels of inflammatory markers and that 18-29% of the variation in these markers could be explained by frequency of heat strain. Firefighters themselves are susceptible to core temperatures ranging between 38.5 and 39.0C in as little as 2-3 work cycles. Considering resource limitation in the fire service, such workloads is a realistic possibility when at structural fires, particularly for first alarm apparatus. Though there is a well-defined role of the inflammatory response in adaptive changes, elevated resting levels begs the question of whether such frequency of exposure and acute inflammatory flux in fire service workers may contribute to chronic elevations of inflammatory markers and altered disease risk. Elevations in c-reactive protein are associated with cardiovascular risk with studies indicating a causative role of monomeric c-reactive protein in platelet activation and thrombus growth. Cooling methods save for cryotherapy have demonstrated limited to mild effectiveness for mitigating the inflammatory responses to heat strain resulting in no solution to attenuate acute inflammatory responses. The mast-cell stabilizing properties of desloratadine and its safety profile make it an interesting candidate for investigating its use in this context. This study seeks to determine whether 10mg desloratadine taken before and 24h after exertional heat strain to a core temperature to a core temperature of 39.5 degrees celsius reduces the associated inflammatory response measured over a 72-hour period.

Interventions

DRUGDesloratadine

Oral ingestion 10mg pill 2 hours prior to heat strain trial. Second 10mg dose 24-hours later.

DRUGPlacebo

Oral ingestion 10mg inert pill 2 hours prior to heat strain trial. Second dose 24-hours later.

OTHERNo Intervention

No pill ingestion during the trial - to discern the presence of a placebo effect from baseline inflammatory response

Sponsors

University of Victoria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Own-control study - all participants perform each trial arm/intervention separated by a washout period. Order of trials is randomized for each participant.

Eligibility

Sex/Gender
MALE
Age
19 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Demonstrated willingness to participate in the study and adhere to procedures by signing a written informed consent * Biological males aged 19-50 * Successful Physical Activity Readiness Questionnaire (PAR-Q) * Ability to swallow core temperature capsule * VO2Max \>35 mL/kg/min * No allergy or current dosage of H1 histamine receptor antagonists * Participants must be in good health with no 'Category A' diseases/conditions outlined in National Fire Protection Association (NFPA) 1582 (https://www.iafc.org/docs/default-source/1vcos/vws\_rrkit\_nfpa-1582.pdf?sfvrsn=ca9b9f0d\_2)

Exclusion criteria

* Biological females * Males below age of 19, and 51-years or older * Unsuccessful PAR-Q * VO2Max below 35 mL/kg/min * Allergy to H1 histamine receptor antagonists * Esophageal constriction (inability to swallow core temperature capsule) * Any condition or disease listed as 'Category A' in NFPA 1582 that would disqualify a person as a firefighter. * Current use of NSAIDS or steroid drugs (oral or nasal). * Consumption of caffeine, nicotine, or alcohol in the preceding 12-hours. * Dehydration (urine specific gravity over 1.030) * Recent cold/flu (at least 7-days clear of symptom resolution) * No use of antibiotics in preceding 14-days. * Dosing of medication that is known to exhibit adverse reactions with desloratadine dosing.

Design outcomes

Primary

MeasureTime frameDescription
Change in serum interleukin-6 and ELISABefore, immediately following, and 2-hours following exertional heat strainAssessment of changes in serum interleukin-6 within and between interventions measured via venipuncture and ELISA
Change in serum cortisolBefore, immediately following, and 2-hours following exertional heat strainAssessment of changes in serum cortisol within and between interventions measured via venipuncture and ELISA
Change in serum c-reactive proteinBefore, immediately following, and 24, 48, and 72-hours following exertional heat strainAssessment of changes in serum c-reactive protein within and between interventions measured via venipuncture and ELISA
Change in serum tumor necrosis factor alphaBefore, immediately following, and 2-hours following exertional heat strainAssessment of changes in serum tumor necrosis factor alpha within and between interventions measured via venipuncture and ELISA.

Secondary

MeasureTime frameDescription
Differences in core body heat storageBefore and immediately after exertional heat strainTrial arm differences in the change in core body temperature during heating.
Change in body massBefore and immediately after exertional heat strainTrial arm differences in fluid loss estimated via differences between before-after body mass.

Other

MeasureTime frameDescription
Differences in Cerebral Blood FlowBefore and immediately after (following assessment of outcome 8 and 9) exertional heat strainWithin and between intervention differences in cerebral blood flow changes via vascular duplex ultrasound and hypercapnia
Differences in brain blood oxygenation of prefrontal cortexBefore and immediately after exertional heat strainWithin and between intervention differences in prefrontal cortex oxygenation via near-infrared spectroscopy
Differences in heart rate (HR) and heart rate variability (HRV)Before and immediately after exertional heat strainWithin and between intervention differences in HR and HRV

Countries

Canada

Contacts

Primary ContactThomas W Service, MSc
service1@uvic.ca2508964682

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026